Terms: = Liver cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Diagnosis
23 results:
1. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
[TBL] [Abstract] [Full Text] [Related]
2. idh-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall.
Sekita T; Yoshida A; Kawai A; Ichikawa H; Kobayashi E
Genes Chromosomes Cancer; 2023 Dec; 62(12):755-760. PubMed ID: 37732625
[TBL] [Abstract] [Full Text] [Related]
3. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract] [Full Text] [Related]
4. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
Faria C; Tzankov A
Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
[TBL] [Abstract] [Full Text] [Related]
5. Bile duct adenoma and small-sized small duct type intrahepatic cholangiocarcinoma show distinct differences in genetic alterations, expression of IMP3 and EZH2 and stromal and inflammatory components.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2023 Aug; 83(2):298-309. PubMed ID: 37140546
[TBL] [Abstract] [Full Text] [Related]
6. [Current Studies and Evidence in Cholangiocarcinoma].
Zimpel C; Mitzlaff K; Jasper NA; Marquardt JU
Zentralbl Chir; 2022 Aug; 147(4):389-397. PubMed ID: 35863357
[TBL] [Abstract] [Full Text] [Related]
7. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract] [Full Text] [Related]
8. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract] [Full Text] [Related]
9. Genetic, Clinicopathological, and Radiological Features of Intrahepatic Cholangiocarcinoma with Ductal Plate Malformation Pattern.
Chung T; Rhee H; Shim HS; Yoo JE; Choi GH; Kim H; Park YN
Gut Liver; 2022 Jul; 16(4):613-624. PubMed ID: 34810298
[TBL] [Abstract] [Full Text] [Related]
10. idh Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
[TBL] [Abstract] [Full Text] [Related]
11. [Recent progress in molecular targeted therapies for intrahepatic cholangiocarcinoma].
Xie ZH; Li J; Xia Y; Shen F
Zhonghua Wai Ke Za Zhi; 2020 Apr; 58(4):289-294. PubMed ID: 32241059
[TBL] [Abstract] [Full Text] [Related]
12. [Personalized treatment of cholangiocellular carcinoma (CCA)].
Jödicke L; Zender L; Malek NP
Internist (Berl); 2020 Feb; 61(2):170-174. PubMed ID: 31938815
[TBL] [Abstract] [Full Text] [Related]
13. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract] [Full Text] [Related]
14. Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma?
Malvi D; de Biase D; Fittipaldi S; Grillini M; Visani M; Pession A; D'Errico A; Vasuri F
Histopathology; 2020 Jan; 76(2):265-274. PubMed ID: 31374137
[TBL] [Abstract] [Full Text] [Related]
15. A Case of Metastatic Biliary Tract cancer Diagnosed Through Identification of an
Kamath SD; Lin X; Kalyan A
Oncologist; 2019 Feb; 24(2):151-156. PubMed ID: 30352944
[TBL] [Abstract] [Full Text] [Related]
16. Mucinous intrahepatic cholangiocarcinoma: a distinct variant.
Chi Z; Bhalla A; Saeed O; Cheng L; Curless K; Wang HL; Patil DT; Lin J
Hum Pathol; 2018 Aug; 78():131-137. PubMed ID: 29698701
[TBL] [Abstract] [Full Text] [Related]
17. Molecular genomic landscapes of hepatobiliary cancer.
Shibata T; Arai Y; Totoki Y
Cancer Sci; 2018 May; 109(5):1282-1291. PubMed ID: 29573058
[TBL] [Abstract] [Full Text] [Related]
18. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract] [Full Text] [Related]
19. Mutational landscape of intrahepatic cholangiocarcinoma.
Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
[TBL] [Abstract] [Full Text] [Related]
20. Molecular diagnosis of intrahepatic cholangiocarcinoma.
Haga H; Patel T
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
[TBL] [Abstract] [Full Text] [Related]
[Next]
